ENDOV

Across TCGA pan-cancer cohorts, ENDOV mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated ENDOV data layer compared with 23 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in glioblastoma multiforme (GBM), where higher ENDOV mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated ENDOV expression acts as an unfavorable survival marker, although some lineages such as GBM and LSCC show a favorable association.

GBM, CCRCC, and LUAD are the cancer types where ENDOV mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
GBM	DFS	Tertile	All	0.942	0.416	.024	6	view →
CCRCC	OS	Quartile	II,III,IV	0.132	0.985	.038	6	view →
LUAD	DFS	Quartile	All	0.509	0.817	.021	4	view →
LSCC	DFS	Tertile	III,IV	0.850	0.248	.031	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

ENDOV–GBM (DFS)

Open the GBM breakdown →